High-dose corticosteroid therapy in COVID-19: the RECOVERY trial

Numerous clinical studies reported extensive inflammation, cytokine storm, and immunopathology in critically ill patients with fatal COVID-19 compared with lower inflammatory responses in COVID-19 patients with mild to moderate disease.2 Dexamethasone treatment reduces neutrophil influx, blocks T-ce...

Full description

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 403; no. 10434; pp. 1338 - 1339
Main Authors Narasaraju, Teluguakula, Ravi, Yazhini, Jonsson, Colleen B, Chow, Vincent T K
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 06.04.2024
Elsevier Limited
Subjects
C-reactive protein
Clinical trials
COVID-19
Cytokine storm
Cytokines
Dexamethasone
Health services
Hyperglycemia
Immunosuppression
Inflammation
Kinases
Leukocytes (neutrophilic)
Lymphocytes T
Neutrophils
Oxygen
Patients
Proteins
Recovery
Steroids
Online AccessGet full text

Cover

More Information
Summary:Numerous clinical studies reported extensive inflammation, cytokine storm, and immunopathology in critically ill patients with fatal COVID-19 compared with lower inflammatory responses in COVID-19 patients with mild to moderate disease.2 Dexamethasone treatment reduces neutrophil influx, blocks T-cell response, and diminishes cytokine storm; however, excessive doses can potentially trigger immunosuppression.3 The earlier RECOVERY trial found significant protection with low-dose dexamethasone treatment (6 mg per day) in severely ill COVID-19 patients.4 COVID-19 patients recruited in this earlier trial received oxygen or no oxygen and displayed characteristics of mild to moderate disease—thus, extreme caution was taken in selecting the dosage of dexamethasone to prevent dexamethasone-induced immunosuppression in these patients. [...]although initial C-reactive protein concentrations of over 75 mg/L were measured in the inclusion criteria of patients, follow-up tests on C-reactive protein concentrations during this 28-day trial were unclear. Fourth, it is unclear whether the patients with high-dose dexamethasone treatment discharged after the 28-day trial period had prolonged complications such as hyperglycaemia or other superinfections. Since dexamethasone treatment is known to prolong immune deficiency and induce hyperglycaemia, post-recovery monitoring for several months to assess the deleterious effects of dexamethasone in these patients is essential.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(23)02884-2